On Tuesday, Catalyst Pharmaceuticals stock hit an important technical milestone, with its Relative Strength (RS) Rating climbing into the 80-plus percentile with an improvement to 83, up from 79 the day before.
This exclusive rating from Investor's Business Daily measures price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains tend to have an RS Rating north of 80 in the early stages of their moves.
Risk Management In The Stock Market: How Much Money To Invest Now
Is Catalyst Pharmaceuticals Stock A Buy?
Catalyst Pharmaceuticals stock is working on a consolidation with a 17.50 entry. See if the biotech stock can break out in volume at least 40% higher than normal.
The biotech company reported -7% earnings growth in its most recent report, while sales growth came in at 15%.
Catalyst Pharmaceuticals stock earns the No. 9 rank among its peers in the Medical-Biomed/Biotech industry group. Halozyme Therapeutics, United Therapeutics and Vertex Pharmaceuticals are among the top 5 highly rated stocks within the group.
